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which significantly reduces the incidence of break- 
through IFI, may more be effective than treatment 
of established IFIs. 
Patients with IFIs POS (n = 16) FLU (n = 27) 
Total deaths, n (%) 10 (63) 18 (67) 
Cause of death, n (%) 
Progression of IFI 2 (13) 6 (22) 
HSCT/GVHD 2 (13) 6 (22) 
Adverse events 6 a (38) 5 b (19) 
Unknown 0 1 (4) 
alnc[udes: intracrania[ hemorrhage, brain stem herniation, bac- 
teria[ sepsis, cardiopu[monary arrest, disseminated varicella 
zoster, upper ~astrointestina[ b[eed. 
blnc[udes: diffuse a[veo[ar hemorrhage, cardiac and respiratory 
fai[ure, cytornesalovirus pneumonia, respiratory insufficiency. 
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Risk Factors for Adenoviral Disease in Pediatric 
AIIogeneic Stem Cell Transplant Recipients 
E.J. Anderson 1 *, K. Thormann 1, M. K[etze[ ~, 
J.A. Guzma-Cottri[[ 2, X. Zheng ~, B.Z. Katz ~. 
1Children's/Memorial Hospital, Chicago, IL, 
USA, 2Oregon Health and Science University, 
Portland, OR, USA 
Background: Risk factors for adenovirus (ADV) in- 
fection following a[[ogeneic stem ceil transplan- 
tation (ASCT) from retrospective studies include 
graft versus host disease (GVHD), T-ceil depleted 
grafts, [ymphopenia, retransp[antation, total body 
irradiation, use of multiple immunosuppressives, 
and mismatched or unrelated donors. 
Objectives: To perform a case-control study to 
ascertain risk factors for ADV infection in pediatric 
ASCT patients (pts). 
Methods: We prospectively studied 40 children 
from 9/8/03 to 12/1/05 for ADV infection for up 
to 1 year (y) following ASCT. The week prior to 
ASCT, a throat swab, urine, and stool were sent for 
viral culture, and plasma was sent for ADV PCR. The 
same specimens were obtained weekly for the first 
100 days (d), then monthly until 1 y after ASCT. We 
defined ADV infection as: (1) a positive ADV PCR, 
(2) >2 positive ADV cultures from separate sites, or 
(3) 1 positive culture plus clinical evidence of ADV. 
1 ADV infected pt was matched with 2 non-infected 
pts for gender and survival to at [east 21 d after the 
index case developed ADV. Risk factors were then 
compared. 
Results: 6 (15%) of the 40 ASCT pts developed 
ADV infection. Median age of case pts was 1.4y, 
while that of control pts was 9.3y. 2 of 6 
case pts received anti-thymocyte globulin (ATG) 
post-transplant as opposed to 0 of 2 matched 
controls. 2 of 6 case pts underwent previous ASCT 
compared with 1 of 12 controls. Case pts recovered 
their lymphocyte counts to 200/ram 3 a median of 
18.5 d following transplant while control pts were 
14 d. Matched related transplants occurred in only 
1 of 6 case pts but in 6 of 12 control pts. There 
were no differences between case and control pts 
regarding ethnicity, diagnosis leading to transplant, 
pretreatment conditioning, episodes of GVHD, or 
treatment with gancic[ovir. 
Conclusions: Younger age, receipt of ATG post- 
transplant, and a longer time to lymphocyte re- 
covery appeared to be risk factors for developing 
ADV infection. GVHD, total body irradiation, and 
conditioning regimen were not. Receipt of a trans- 
plant from a completely matched related donor 
appeared protective. 
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Factors Influencing CMV Seropositivity in 
Stem Cell Transplant (SCT) Patients and Donors 
R Ljungman*, R. Brand. Karolinska University 
Hospital, Stockholm, Sweden 
Background: CMV remains an important factor for 
outcome of a[[ogeneic stem ceil transplantation 
(SCT). The serological status of both donors and 
recipients are important factors for transplant out- 
come. 
Objective: Our aim was use the registry of the Eu- 
ropean Group for Blood and Marrow Transplantation 
to study trends over time as we[[ as analyzing the 
effects of age, gender, and country on the donor 
and recipient CMV serostatus. 
Patients ~ Methods: 40,311 patients and 23,048 
donors were selected from the registry database. 
The patients were transplanted 1985-2004. Logis- 
tic regression models were constructed predicting 
seropositivity using as covariates year of SCT, age, 
gender, and country for both patients and donors 
separately. 
Results: Females had a higher likelihood to be 
seropositive than males both among patients 
(OR 1.22; 1.15-1.30; p<.001) and donors (OR 1.23; 
1.13-1.34; p<0.001). The risk to be seroposi- 
tive increased by age (patients OR 1.19/decade; 
1.17-1.21; p<0.001; donors OR 1.24/decade; 
1.22-1.27; p<0.001) but decreased by calendar 
year (patients OR 0.98/year, 0.97-0.99; p < 0.001; 
donors 0.98/year; 0.97-0.98; p=0.001). There 
were major differences between different coun- 
tries with the BENELUX countries having the lowest 
and Italy the highest probabilities to be seroposi- 
tive for both patients and donors. 
Infections in Stem Ce[[ Transp[ant Recipients $29 
Conclusions: The tiketihood of being CMV seroposi- 
tire is higher in femates and order individuats. The 
risk has been decreasing over time both SCT pa- 
tients and their donors. The tiketihoods vary greatty 
between different countries. 
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Infectious Complications in Patients Treated for 
Hematological Malignancies 
C. Orasch J6rg*, M. Weisser, A. Widmer, 
M. Battegay, S. Christen, D. Helm, A. Gratwoht, 
U. Ftuckiger. Division of Infectious Diseases Et 
Hospital Epidemiology, University Hospital Basel, 
Switzerland 
Background: Infections are a reading cause of 
comptications in patients treated with high-dose 
chemotherapy and/or hematopoietic stem cett 
transptantation (HSCT) for hematotogicat matig- 
nancies. 
Methods: In a prospective observationat cohort 
study we recorded art btoodstream infections (BSI) 
and art new putmonary infittrates in patients hospi- 
tatized at the Hematotogic Reverse Isotation Unit of 
the University Hospitat Base[ from Jury 2003 untit 
June 2005. Putmonary infittrates were separated 
into bacteriat or fungat pneumonia according to 
microbiotogicat and radiotogicat findings. Invasive 
aspergillosis (IA) was ctassified as proven, proba- 
bte or possibte according to EORTC/MSG consensus 
definitions. 
Results: From Jury 2003 to June 2005, 160 pa- 
tients with 249 episodes of hospitatization were 
included. 91 (36%) episodes occurred during at- 
togeneic HSCT, 40 (16%) to autotogous HSCT and 
118 (47%) to induction/consotidation chemothera- 
pies. We noted 44 (18%) episodes of BSI (incidence 
13.8/1000 days of neutropenia), 53 (21%) episodes 
of pneumonia (incidence 17.3/1000 days of neu- 
tropenia) and 35 (14%) episodes of IA (26 possibte, 
5 probabte, 4 proven). IA occurred in 15/95 (16.5%) 
attogeneic HSCTs, in 16/118 (16%) chemotherapies 
and in onty 1/40 (2.6%) episodes of autotogous 
HSCT. The highest incidence of infectious compti- 
cations was seen in patients undergoing attogeneic 
HSCT (59/91, 65%), fottowed by patients receiving 
high-dose chemotherapies (58/118, 49%) and [ow- 
est after autotogous HSCT (12/40, 30%). Overatt 
in-hospitat mortatity was 13%; 12% in attogeneic 
HSCT, 8% in chemotherapies and 0% in autotogous 
HSCT. 
Conclusion: The incidence of BSI was tower 
than reported in the titerature, possibty retated 
to the routine use of chtorhexidine-suffadiazine- 
coated catheters. The incidence of pneumonia was 
higher probabty because of the regutarty performed 
CT scans. However, the IA rate was comparabte to 
the titerature. 
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Long-Term Suppressive Acyclovir (ACV) Use 
Reduces Varicella Zoster (VZV) Diseases 
and Emergence of ACV-Resistant Herpes 
Simplex Viruses (HSV) After Stem Cell 
Transplantation (HCT) 
V. Erard*, A. Ward, W. Leisenring, C. Vartey, 
J. Heuget, L. Corey, M. Boeckh. Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA 
Background: One-yr ACV use effectivety reduces 
VZV disease at one yr after attogeneic HCT, but VZV 
disease continues to occur in patients on persistent 
immune suppression (Boeckh et at. Brood, 2006). 
Objectives: To determine the efficacy of two tong- 
term suppressive ACV regimens sequentiatty intro- 
duced at the Fred Hutchinson Cancer Research 
Center (FHCRC) in preventing VZV disease after 
attogeneic HCT. To evatuate the impact of tong- 
term suppressive ACV use on ACV-resistant HSV 
disease. 
Methods: Three cohorts of VZV seropositive T 
cett reptete attogeneic HCT recipients were ex- 
amined: cohort 1 (no ACV; before 1999, N=722), 
cohort 2 (ACV 800 mg or VACV 500 mg BID for 1 yr; 
1999-2002; N= 851 ), and cohort 3 (ACV/VACV as in 
cohort 2 ptus extended use in patients on contin- 
ued immunosuppressive drugs at 1 yr; 2002-2003, 
N = 402). The crude incidence rates of VZV disease 
in the 3 cohorts were catcutated at 1 yr and at 2yrs 
after HCT. Rate ratios (RR) were estimated by the 
Mantet-Haenszet person-time chi-square statistic. 
The probabitity of first VZV disease was evatuated 
using cumutative incidence estimates. The tog-rank 
test was used to assess the equatity of CI curves. In- 
cidence of taboratory proven HSV and ACV-resistant 
HSV disease was compared between the groups us- 
ing the fisher exact test. P vatues were two-sided. 
Results: At 1 yr after HCT, VZV disease decreased 
from 35.2 per 100 person-yrs in cohort 1 to 4.5 in 
cohort 2 and 1.4 in cohort 3; by two yrs after HCT, 
VZV disease decreased from 28 per 100 person- 
yrs in cohort 1 to 7.3 in cohort 2 and 3.6 in 
cohort 3. The incidence rate ratio (RR) comparing 
cohort 2 and cohort 3 to cohort 1 was 0.26 (95%CI 
0.20-0.34, p<0.001) and 0.12 (95%CI 0.07-0.21, 
p < 0.001), respectivety. RR comparing cohort 3 to 
cohort 2 was 0.48 (95%CI 0.28-0.84, p=0.008). 
The fraction of cases of VZV disease prevented 
exctusivety by ACV in cohort 2 and in cohort 3 was 
73% and 87% respectivety. One-yr (cohort 2) and 
